In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer

The role of immunotherapy in small cell lung cancer

(2019) A. Calles et al.   Clinical & Translational Oncology

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

(2019) Zebin Wang et al.   Scientific Reports

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial

(2019) Jean-Louis Pujol et al.   Journal of Thoracic Oncology

Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells

(2019) Huanhuan Joyce Chen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

67TiPADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer

(2019) S Senan et al.   ANNALS OF ONCOLOGY

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

(2019) T K Owonikoko et al.   ANNALS OF ONCOLOGY

Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study

(2019) Anish Thomas et al.   Journal of Thoracic Oncology

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

(2019) Megumi Furuta et al.   ONCOLOGIST

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

(2019) Constantia Pantelidou et al.   Cancer Discovery

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study

(2019) Daniel Morgensztern et al.   CLINICAL CANCER RESEARCH

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

(2019) A. Pavan et al.   Journal for ImmunoTherapy of Cancer

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

(2019) M Reck et al.   ANNALS OF ONCOLOGY

LBA89PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

(2019) L Paz-Ares et al.   ANNALS OF ONCOLOGY

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study

(2018) M.J. Edelman et al.   Journal of Thoracic Oncology

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

(2018) Shirish M. Gadgeel et al.   Journal of Thoracic Oncology

Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung

(2018) Hye Sook Kim et al.   Journal of Thoracic Oncology

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer

(2018) Kentaro Tanaka et al.   LUNG CANCER

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

(2018) Christopher W. Mount et al.   NATURE MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study

(2018) M Thomas et al.   ANNALS OF ONCOLOGY

Abstract CT145: A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma

(2018) Karin Straathof et al.   CANCER RESEARCH

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes

(2018) L. Bonanno et al.   EUROPEAN JOURNAL OF CANCER

Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance

(2018) Etienne Giroux-Leprieur et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory small cell lung cancer.

(2018) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.

(2018) Anna F. Farago et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).

(2018) Jonathan Wade Goldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

(2018) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

(2018) Alex H. Wagner et al.   Nature Communications

Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition

(2018) Deshui Jia et al.   Cancer Discovery

LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

(2018) M Reck et al.   ANNALS OF ONCOLOGY

1665PDPreliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study

(2018) I Bondarenko et al.   ANNALS OF ONCOLOGY

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts

(2018) R T Penson et al.   ANNALS OF ONCOLOGY

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

(2018) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage

(2018) Jung Wook Park et al.   SCIENCE

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

Second-line treatments of small-cell lung cancers

(2017) Nathalie Baize et al.   Expert Review of Anticancer Therapy

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

(2017) June-Koo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC

(2017) Penella Woll et al.   Journal of Thoracic Oncology

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

(2017) Erik Thunnissen et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

(2017) Toshiaki Takahashi et al.   LANCET ONCOLOGY

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

MHC class II expression in lung cancer

(2017) Yayi He et al.   LUNG CANCER

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Unravelling the biology of SCLC: implications for therapy

(2017) Joshua K. Sabari et al.   Nature Reviews Clinical Oncology

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer

(2017) Karen McColl et al.   Oncotarget

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

(2017) Robert J. Cardnell et al.   Oncotarget

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

(2017) Charles Dayen et al.   Journal of Thoracic Disease

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

(2017) M. Hardy-Werbin et al.   OncoImmunology

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

(2016) L.V. Sequist et al.   ANNALS OF ONCOLOGY

STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT

(2016) D. De Ruysscher et al.   ANNALS OF ONCOLOGY

Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

(2016) T.K. Owonikoko et al.   ANNALS OF ONCOLOGY

Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus

(2016) Matt L. Harlow et al.   CANCER RESEARCH

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer Subtypes Generate Unique Immune Responses

(2016) Stephanie E. Busch et al.   JOURNAL OF IMMUNOLOGY

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

(2016) Edurne Arriola et al.   Journal of Thoracic Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

(2016) G. Santamaria Nunez et al.   MOLECULAR CANCER THERAPEUTICS

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

(2016) Mark D. Borromeo et al.   Cell Reports

Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer

(2015) Kosuke Fujino et al.   AMERICAN JOURNAL OF PATHOLOGY

PD-L1 expression in small cell neuroendocrine carcinomas

(2015) Anne M. Schultheis et al.   EUROPEAN JOURNAL OF CANCER

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

(2015) Hidenobu Ishii et al.   Journal of Thoracic Oncology

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

(2015) Ben J Slotman et al.   LANCET

Abstract B169: A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib

(2015) Keith Mikule et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

(2015) J T Poirier et al.   ONCOGENE

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

(2014) M. E. Elez et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer

(2014) Anish Thomas et al.   Journal of Thoracic Oncology

Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells

(2014) YIMIN LU et al.   ONCOLOGY REPORTS

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) M. Fruh et al.   ANNALS OF ONCOLOGY

Histologic Assessment of Tumor-Associated CD45 + Cell Numbers Is an Independent Predictor of Prognosis in Small Cell Lung Cancer

(2013) Wei Wang et al.   CHEST

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

(2013) Mahiuddin Ahmed et al.   FEBS LETTERS

Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer

(2013) J. T. Poirier et al.   JNCI-Journal of the National Cancer Institute

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer

(2013) Anne M Schultheis et al.   MODERN PATHOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells

(2012) S Kalari et al.   ONCOGENE

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

Immunization with N-propionyl polysialic acid–KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci

(2011) Lee M. Krug et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines

(2010) Barbara Gerratana   MEDICINAL RESEARCH REVIEWS

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage

(2008) K. Koyama et al.   CLINICAL CANCER RESEARCH